ı	n PTO V 5-93)		ATTORNEY'S DOCKET NUMBER P51364							
	-	TRANSMITTAL LETTER T DESIGNATED / ELECTE CONCERNING A FILING	U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5) 10/518206							
		IATIONAL APPLICATION NO. US 2003/20346	INTERNATIONAL FILING DATE June 27, 2003	PRIORITY DATE CLAIMED June 27, 2002						
TIT	TITLE OF INVENTION Carvedilol Hydrobromide									
APPLICANT(S) FOR DO/EO/US Pingyun Y. CHEN, Qunying DAI, Philip C. DELL'ORCO, Claire HISLER, David H. IGO, Le										
M. KATRINCIC, Clifford S. LABAW and Li-Jen PING Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:										
1 2.	[]	This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.								
3.	[x]	This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).								
4.	[x]	A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.								
5.	[x]	A copy of the International Application as filed (35 U.S.C. 371(c)(2)) a. [] is transmitted herewith (required only if not transmitted by the International Bureau). b. [x] has been transmitted by the International Bureau. c. [] is not required, as the application was filed in the United States Receiving Office (RO/US).								
6.	[]	A translation of the International Application into English (35 U.S.C. 371(c)(2)).								
7.	[]	Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) a. [] are transmitted herewith (required only if not transmitted by the International Bureau). b. [] have been transmitted by the International Bureau. c. [] have not been made; however, the time limit for making such amendments has NOT expired. d. [] have not been made and will not be made.								
8.	[]	A translation of the amendments to the claims under PCT Article 19 (35 U.S. C. 371(c)(3)).								
9.	[x]	An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).								
10.	[]	A translation of the annexes (35 U.S.C. 371(c)(5)).	s to the International Preliminary Ex	amination Report under PCT Article 36						
			er document(s) or information inc							
		An Information Disclosure Statement under 37 C.F.R. 1.97 and 1.98; and Form PTO-1449. An assignment document for recording. A separate cover sheet in compliance with 37 C.F.R. 3.28 and 3.31 is included.								
		A FIRST preliminary amendment. (Add claim to priority via Preliminary Amendment for US originating cases only)								
		A SECOND or SUBSEQUENT preliminary amendment. A substitute specification.								
		A change of power of attorney and/or address letter.								
17.	[x]	An Abstract on a separate sheet of paper.								
		Copy of Form PCT/ISA/210.								
19.	11	Other items or information.								

US APPLICATION I	5 18206 ^R	1.50) INTERNATIONA PCT/US200	INTERNATIONAL APPLICATION NO. PCT/US2003/20346		ATTORNEYS DOCKET NO. P51364				
20. [X] The fol	llowing fees are submi	CALCULATION	PTO USE ONLY						
Basic	National Fee (37 C.F								
🗷 a) Bas	ic Filing Fee	•							
	mination Fee		~						
	rch Fee								

		\$1,000.00							
	0.00 for furnishing the earliest claimed priori	\$0.00							
Claims	Number Filed	Number Extra	Rate						
Total claims	41 - 20 =	21	21 x \$50.00	\$1,050.00					
Independent claims	10 - 3 =	7	2 x \$200.00	\$1,400.00					
	nt claims (if applicabl	\$0.00							
		\$3,450.00							
	pplication size fee - for addt'l sheets 1 x \$25	\$250.00							
		\$3,450.00							
•	\$130.00 for furnishing the from the earliest c	\$:						
		\$3,450.00							
		Amount to be refunded	\$						
				charged	\$				
a. A check in the amount of \$\square\$ to cover the above fees is enclosed.									

- b. Please charge my Deposit Account No. 19-2570 in the amount of \$3,450.00 to cover the above fees.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

GLAXOSMITHKLINE

Corporate Intellectual Property - UW2220

P.O. Box 1539

King of Prussia, PA 19406-0939

Phone (610) 270-4650

Facsimile (610) 270-5090

SIGNATURE

Grace C. Hsu

NAME

51,336

REGISTRATION NO.



PATENT ATTORNEY'S DOCKET NUMBER P51364

TRANSMITTAL LETTER TO THE U.S. DESIGNATED OFFICE (DO/US) - ENTRY INTO NATIONAL STAGE UNDER 35 USC 371

INTERNATIONAL APP. NO.

INTERNATIONAL FILING DATE PRIORITY DATE CLAIMED

PCT/US2003/20346

June 27, 2003

June 27, 2002

TITLE OF INVENTION

Carvedilol Hydrobromide

APPLICANT(S) FOR DO/US

Pingyun Y. CHEN, Qunying DAI, Philip C. DELL'ORCO, Claire HISLER, David H. IGO,

Lee M. KATRINCIC, Clifford S. LABAW and Li-Jen PING

Commissioner for Patents

Mail Stop: PCT P.O. Box 1450

Alexandria, VA 22313-1450

ATTENTION: DO/US

CERTIFICATION UNDER 37 CFR 1.10

I hereby certify that this Transmittal Letter, Form PTO 1390 and the papers indicated as being transmitted therewith, and Post Card are being deposited with the United States Postal Service on this date <u>December 16, 2004</u> in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number <u>EV608165832US</u> addressed to the:

Commissioner for Patents, Mail Stop: PCT, P.O. Box 1450, Alexandria, VA 22313-1450.

(Typed or printed name of person mailing paper)

(Signature of person mailing paper)

20462

CUSTOMER NUMBER